The lamellar ichthyosis market reached a value of USD 5.3 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 8.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.17% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 5.3 Million |
Market Forecast in 2035
|
USD 8.4 Million |
Market Growth Rate 2025-2035
|
4.17% |
The lamellar ichthyosis market has been comprehensively analyzed in IMARC's new report titled "Lamellar Ichthyosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Lamellar ichthyosis is a rare and inherited skin disorder that falls under the broader category of ichthyosis, which refers to a group of genetic conditions characterized by dry, scaly skin. This particular type is caused by mutations in the gene responsible for forming a protein called transglutaminase-1, leading to the abnormal development of the skin's protective barrier. The symptoms of the ailment typically manifest at birth or within the first few weeks of life. Individuals suffering from the illness may present with thick, plate-like scales covering large areas of their body, often resembling fish scales. The skin can be dry, rough, and prone to cracking, which can cause discomfort and susceptibility to infections. Moreover, these scales may affect the patient's range of motion and lead to restricted movement. The diagnosis of lamellar ichthyosis involves a thorough examination of the skin and family history analysis. Skin biopsies and genetic testing are also crucial steps in confirming the condition.
To get more information of this market, Request Sample
The rising prevalence of somatic mutations in the TGM1 gene, which result in the impaired production of the enzyme transglutaminase-1, leading to the buildup of scale-like skin, particularly affecting the face and body regions, is primarily driving the lamellar ichthyosis market. In addition to this, the escalating adoption of numerous effective medications, including emollients, keratolytics, retinoids, etc., to alleviate symptoms of the ailment and enhance skin barrier function is fostering a positive outlook for the market. Moreover, the widespread implementation of physical and occupational therapies to increase treatment response is further bolstering the market growth. These therapies play a crucial role in managing the condition by promoting mobility, improving limb function, and enhancing overall motor skills. Apart from this, the increasing utilization of phototherapy, since it involves exposing the affected skin to controlled levels of ultraviolet light, thereby boosting the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that works by introducing functional genetic material to correct or replace the faulty TGM1 gene responsible for the disease, providing long-term relief to patients, is expected to drive the lamellar ichthyosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the lamellar ichthyosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for lamellar ichthyosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lamellar ichthyosis market in any manner
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current lamellar ichthyosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
KB 105 | Krystal Biotech, Inc |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Lamellar Ichthyosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies